ZURICH (Reuters) - Swiss drugmaker Novartis said on Friday a final stage test of Jakavi, used to treat patients with a rare blood cancer, had met its primary endpoint and improved two key measures of disease control in patients.
via Reuters: Health News Read More Here..
No comments:
Post a Comment